Desbutylhalofantrine: Evaluation of QT prolongation and other cardiovascular effects after intravenous administration in vivo

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 3, 2003, Pages 406-413

  McIntosh, Michelle P ^a,b   Batey, Andrew J ^a   Porter, Christopher J H ^b   Charman, William N ^b   Coker, Susan J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Desbutylhalofantrine; Electrocardiographic intervals; Halofantrine; Hemolysis; QT prolongation

Indexed keywords

DEBUTYLHALOFANTRINE; HALOFANTRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HEART RATE; HEART REPOLARIZATION; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LONG QT SYNDROME; MALE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RABBIT;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEART RATE; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; PHENANTHRENES; RABBITS;

EID: 0037369463     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200303000-00009     Document Type: Article

References (30)

1. Horton RJ, Parr SN, Bokor LC. Clinical experience with halofantrine in the treatment of malaria. Drugs Exp Clin Res. 1990;16:497-503.
2. Boudreau EF, Pang LW, Dixon KE, et al. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bull World Health Organ. 1988;66:227-35.
3. Rinehart J, Arnold J, Canfield CJ. Evaluation of two phenanthrenemethanols for antimalarial activity in man: WR 122,433 and WR 171,669. Am J Trop Med Hyg. 1976;25:769-74.
4. Basco LK, Gillotin C, Gimenez F, et al. Antimalarial activity in vitro of the N-desbutyl derivative of halofantrine. Trans R Soc Trop Med Hyg. 1992;86:12-3.
5. ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993;341:1044-9.
6. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1993;341:1054-6.
7. Bradley DJ. Antimalarial prophylaxis: manufacturers recommend more stringent guidelines for halofantrine. BMJ. 1994;308:721.
8. Foley M, Tilley L. Quinoline antimalarials: mechanism of action and resistance and prospects for new agents. Pharmacol Ther. 1998;79:55-87.
9. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52:818-36.
10. Karbwang J, Bangchang KN, Bunnag D, et al. Cardiac effects of halofantrine. Lancet. 1993;342:501.
11. Touze JE, Bernard J, Keundjian A, et al. Electrocardiographic changes and halofantrine plasma levels during acute falciparum malaria. Am J Trop Med Hyg. 1996;54:225-8.
12. Lightbown ID, Lambert JP, Edwards G, et al. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. Br J Pharmacol. 2001;132:197-204.
13. Wesche DL, Schuster BG, Wang WX, et al. Pharmacodynamics and drug action: mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther. 2000;67:521-9.
14. Coker SJ, McIntosh MP, Batey AJ, et al. QTc prolongation by desbutylhalofantrine, the metabolite of the antimalarial drug halofantrine. Proc Aust Soc Clin Exp Pharmacol Toxicol. 2000;7:44.
15. Bazett HC. An analysis of the time-relation of electrocardiograms. Heart. 1920;7:353-70.
16. Humberstone AJ, Currie GJ, Porter CJH, et al. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J Pharm Biomed Anal. 1995;13:265-72.
17. Sutton TJ, Luke JSH, Jones HB. Red cell haemolysis induced by SK&F 95018: a combined vasodilator and β-adrenoceptor antagonist. Hum Toxicol. 1988;7:243-8.
18. Husa WJ, Adams JR. Isotonic solutions: II: the permeability of red corpuscles to various substances. J Am Pharmacol Assoc. 1944;33:329-35.
19. Monlun E, Le Metayer P, Szwandt S, et al. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg. 1995;89:430-3.
20. Batey AJ, Lightbown ID, Lambert JP, et al. Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea pigs. Br J Pharmacol. 1997;122:563-9.
21. Kr: implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-11.
22. Bennett M, Desforges JF. Quinine-induced haemolysis: mechanism of action. Br J Haematol. 1967;13:706-12.
23. Laser H, Kemp P, Miller N, et al. Malaria, quinine and red cell lysis. Parasitology. 1975;71:167-81.
24. Van den Ende J, Coppens G, Verstraeten T, et al. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health. 1998;3:632-9.
25. Vachon F, Fajac I, Gachot B, et al. Halofantrine and acute intravascular haemolysis. Lancet. 1992;340:909-10.
26. Mojon M, Wallon M, Gravey A, et al. Intravascular haemolysis following halofantrine intake. Trans R Soc Trop Med Hyg. 1994;88:91.
27. + loss, reduction in repolarization, time and tissue ATP levels during myocardial hypoxia and ischemia. Circ Res. 1993;72:560-70.
28. Bethell HWL, Vendenberg JI, Smith GA, et al. Changes in ventricular repolarization during acidosis and low-flow ischemia. Am J Physiol. 1998;44:H551-61.
29. Spitzer KW, Hogan PM. The effects of acidosis and bicarbonate on action potential repolarization in canine cardiac Purkinje fibers. J Gen Physiol. 1979;73:199-218.
30. Opie LH. The heart: physiology, from cell to circulation, 3rd ed. Philadelphia: Lippincott-Raven, 1998.